Navigation

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)

Cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal

Status: History
Expected date of issue: January 2012
Process: MTA
Topic area:
  • Cancer
  • Digestive system
 

NICE project team

Executive Lead: Peter Littlejohns
Technical Lead: Helen Tucker
Communications manager: Alice Law
Project manager: Jeremy Powell
Top


 

Provisional schedule

Consultation on draft scope by stakeholders: 29 July 2010
Closing date for invited submissions / evidence submission: 15 February 2011
1st appraisal committee meeting: 04 August 2011
2nd appraisal committee meeting: 05 October 2011
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Merck Serono (cetuximab)
  • Roche Products (bevacizumab)
  • Amgen (panitumumab)

Patient/carer groups

  • Beating Bowel Cancer
  • Bowel Cancer UK
  • europacolon

Professional groups

  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians
  • United Kingdom Oncology Nursing Society

Others

  • Department of Health
  • NHS Telford and Wrekin
  • Welsh Assembly Government

General

  • British National Formulary
  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare improvement Scotland (formally NHS Quality Improvement Scotland)

Comparator manufacturer(s)

  • Actavis UK (oxaliplatin irinotecan) – not participating, did not return confidentiality form
  • Hospira UK (oxaliplatin, fluorouracil, irinotecan, calcium folinate, calcium levofolinate) - – not participating, did not return confidentiality form
  • Goldshield (fluorouracil) - – not participating, did not return confidentiality form
  • Medac UK (oxaliplatin irinotecan, disodium levofolinate,  fluorouracil)
  • Merck Serono  (tegafur uracil)
  • Pfizer (irinotecan, calcium levofolinate, calcium folinate)
  • Roche Products (capecitabine)
  • Sandoz (irinotecan) – not participating, did not return confidentiality form
  • Sanofi-Aventis (oxaliplatin)
  • Winthrop Pharmaceuticals/Sanofi-Aventis (oxaliplatin) – not participating, did not return confidentiality form

Relevant research groups

  • MRC Clinical Trials Unit
  • National Cancer Research Institute

Assessment Group

  • National Institute for Health Research Health Technology Assessment Programme
  • Peninsula Technology Assessment Group, University of Exeter (PenTAG)

Associated guideline groups

  • National Collaborating Centre for Cancer

Associated public health groups

  • None

Top


 

Key documents

This page was last updated: 05 July 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.